The stock price of Bausch Health Companies Inc (NYSE: BHC) has jumped by 1.95 compared to previous close of 6.66. Despite this, the company has seen a gain of 9.52% in its stock price over the last five trading days. businesswire.com reported 2025-06-26 that VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”). In addition, the compa.
Is It Worth Investing in Bausch Health Companies Inc (NYSE: BHC) Right Now?
The stock has a 36-month beta value of 0.41. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BHC is 290.67M, and at present, short sellers hold a 2.98% of that float. On July 02, 2025, the average trading volume of BHC was 2.52M shares.
BHC’s Market Performance
BHC stock saw an increase of 9.52% in the past week, with a monthly gain of 49.89% and a quarterly increase of 4.95%. The volatility ratio for the week is 5.03%, and the volatility levels for the last 30 days are 5.06% for Bausch Health Companies Inc (BHC). The simple moving average for the last 20 days is 18.72% for BHC’s stock, with a simple moving average of -1.86% for the last 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Piper Sandler repeating the rating for BHC by listing it as a “Underweight.” The predicted price for BHC in the upcoming period, according to Piper Sandler is $3 based on the research report published on August 02, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BHC reach a price target of $8. The rating they have provided for BHC stocks is “Mkt Perform” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Buy” to BHC, setting the target price at $16 in the report published on September 20th of the previous year.
BHC Trading at 30.69% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.07% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Paulson John, who purchase 3,564,059 shares at the price of $5.94 back on Jun 13 ’25. After this action, Paulson John now owns 32,791,702 shares of Bausch Health Companies Inc, valued at $21,170,510 using the latest closing price.
Paulson John, the Director of Bausch Health Companies Inc, purchase 1,005,376 shares at $5.47 during a trade that took place back on Jun 12 ’25, which means that Paulson John is holding 29,227,643 shares at $5,499,407 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.65 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.0. The total capital return value is set at 0.06.
Currently, EBITDA for the company is 1.55 billion with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
To sum up, Bausch Health Companies Inc (BHC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
